An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.
Sponsor: Kyowa Hakko Kirin UK, Ltd.
This PHASE3 trial investigates Parkinson's Disease and is currently completed. Kyowa Hakko Kirin UK, Ltd. leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2021 — May 2024 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Oct 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kyowa Hakko Kirin UK, Ltd.
- Kyowa Kirin, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .